1.Parkin, DM, et al. Global cancer statistics, 2002. CA: A Cancer Journal for Clinicians 2005; 55: 74–108.
2.zur Hausen, H. Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2002; 2: 342–350.
3.Woodman, CB, Collins, SI, Young, LS. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 2007; 7: 11–22.
4.Clifford, GM, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991–998.
5.de Sanjose, S, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infectious Diseases 2007; 7: 453–459.
6.Franceschi, S, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. International Journal of Cancer 2006; 119: 2677–2684.
7.Sukvirach, S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. Journal of Infectious Diseases 2003; 187: 1246–1256.
8.Sargent, A, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. British Journal of Cancer 2008; 98: 1704–1709.
9.Illades-Aguiar, B, et al. Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with no intraepithelial lesions in women from Southern Mexico. Gynecologic Oncology 2010; 117: 291–296.
10.Coupe, VM, et al. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. British Journal of Cancer 2008; 98: 646–651.
11.Chan, PK, et al. Age distribution of human papillomavirus infection and cervical neoplasia reflects caveats of cervical screening policies. International Journal of Cancer 2010; 126: 297–301.
12.Dunne, EF, et al. Prevalence of HPV infection among females in the United States. Journal of the American Medical Association 2007; 297: 813–819.
13.Chao, A, et al. Cervical cancer screening program integrating Pap smear and HPV DNA testing: A population-based study. International Journal of Cancer 2008; 122: 2835–2841.
14.Chao, FY, et al. Defining detection threshold and improving analytical proficiency of HPV testing in clinical specimens. Gynecologic Oncology 2010; 117: 302–307.
15.Lai, CH, et al. Human papillomavirus genotype in cervical cancer: A population-based study. International Journal of Cancer 2007; 120: 1999–2006.
16.Munoz, N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527.
17.Doorbar, J. Molecular biology of human papillomavirus infection and cervical cancer. Clinical Science (London) 2006; 110: 525–541.
18.Castle, PE, et al. Age-related changes of the cervix influence human papillomavirus type distribution. Cancer Research 2006; 66: 1218–1224.
19.Dai, M, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. British Journal of Cancer 2006; 95: 96–101.
20.Zhao, R, et al. Human papillomavirus infection in Beijing, People's Republic of China: a population-based study. British Journal of Cancer 2009; 101: 1635–1640.
21.Hwang, HS, et al. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2470 Korean women determined by DNA chip. Cancer Epidemiology, Biomarkers & Prevention 2004; 13: 2153–2156.
22.Smith, EM, et al. Prevalence and persistence of human papillomavirus in postmenopausal age women. Cancer Detection and Prevention 2003; 27: 472–480.
24.Cheng, HH, et al. An exploration of Papanicolaou smear history and behavior of patients with newly diagnosed cervical cancer in Taiwan. Cancer Nursing 2010; 33: 362–368.
25.Castle, PE, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. British Medical Journal 2009; 339: b2569.